Iams Wealth Management LLC Purchases 13,168 Shares of Novo Nordisk A/S (NYSE:NVO)

Iams Wealth Management LLC lifted its stake in Novo Nordisk A/S (NYSE:NVO - Free Report) by 55.4% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 36,940 shares of the company's stock after purchasing an additional 13,168 shares during the period. Novo Nordisk A/S accounts for 1.2% of Iams Wealth Management LLC's portfolio, making the stock its 21st largest position. Iams Wealth Management LLC's holdings in Novo Nordisk A/S were worth $2,565,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently bought and sold shares of the stock. GQG Partners LLC boosted its stake in shares of Novo Nordisk A/S by 74.7% in the 4th quarter. GQG Partners LLC now owns 12,994,533 shares of the company's stock valued at $1,117,790,000 after purchasing an additional 5,556,460 shares during the last quarter. Raymond James Financial Inc. acquired a new position in Novo Nordisk A/S in the fourth quarter valued at approximately $404,910,000. Loomis Sayles & Co. L P boosted its stake in Novo Nordisk A/S by 34.2% in the fourth quarter. Loomis Sayles & Co. L P now owns 11,571,686 shares of the company's stock valued at $995,397,000 after acquiring an additional 2,947,771 shares during the last quarter. Nuveen Asset Management LLC boosted its stake in Novo Nordisk A/S by 73.2% in the fourth quarter. Nuveen Asset Management LLC now owns 6,244,931 shares of the company's stock valued at $537,189,000 after acquiring an additional 2,639,693 shares during the last quarter. Finally, Two Sigma Investments LP acquired a new stake in Novo Nordisk A/S during the 4th quarter worth $158,657,000. Institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Trading Up 0.7%

NYSE:NVO traded up $0.53 on Thursday, reaching $72.57. The company's stock had a trading volume of 5,088,580 shares, compared to its average volume of 6,858,484. Novo Nordisk A/S has a 1-year low of $57.00 and a 1-year high of $148.15. The business's 50-day moving average price is $65.67 and its two-hundred day moving average price is $81.09. The firm has a market cap of $325.64 billion, a PE ratio of 22.06, a PEG ratio of 0.90 and a beta of 0.66. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, meeting the consensus estimate of $0.92. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. The business had revenue of $11.87 billion for the quarter. Equities research analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on NVO. Dbs Bank lowered Novo Nordisk A/S to a "sell" rating in a research report on Friday, April 25th. Wall Street Zen raised Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a research note on Friday, April 25th. Stifel Nicolaus cut Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. Morgan Stanley started coverage on Novo Nordisk A/S in a research note on Wednesday, February 12th. They issued an "equal weight" rating for the company. Finally, Guggenheim lowered shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research note on Thursday, April 17th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating, four have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus target price of $128.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.